| Symbol | AAVXF |
|---|---|
| Name | ABIVAX SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 75009 France 7-11 boulevard Haussmann |
| Telephone | +33 (0)1 53 83 0841 |
| Fax | — |
| — | |
| Website | https://www.abivax.com/ |
| Incorporation | FR |
| Incorporated On | 2003 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | PricewaterhouseCoopers LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | 0001956827 |
| Description | ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease. Additional info from NASDAQ: Additional info from OTC: |
No news found.
No clinical trials found for this company.
No clinical products found for this company.